Anti-viral defence by an mRNA ADP-ribosyltransferase that blocks translation.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 39443800.
- Also identified by DOI 10.1038/s41586-024-08102-8 and PMC identifier 11618068.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Host-pathogen conflicts are crucibles of molecular innovation<sup>1,2</sup>. Selection for immunity to pathogens has driven the evolution of sophisticated immunity mechanisms throughout biology, including in bacterial defence against bacteriophages<sup>3</sup>. Here we characterize the widely distributed anti-phage defence system CmdTAC, which provides robust defence against infection by the T-even family of phages<sup>4</sup>. Our results support a model in which CmdC detects infection by sensing viral capsid proteins, ultimately leading to the activation of a toxic ADP-ribosyltransferase effector protein, CmdT. We show that newly synthesized capsid protein triggers dissociation of the chaperone CmdC from the CmdTAC complex, leading to destabilization and degradation of the antitoxin CmdA, with consequent liberation of the CmdT ADP-ribosyltransferase. Notably, CmdT does not target a protein, DNA or structured RNA, the known targets of other ADP-ribosyltransferases. Instead, CmdT modifies the N6 position of adenine in GA dinucleotides within single-stranded RNAs, leading to arrest of mRNA translation and inhibition of viral replication. Our work reveals a novel mechanism of anti-viral defence and a previously unknown but broadly distributed class of ADP-ribosyltransferases that target mRNA.
Medical subject headings
- ADP Ribose Transferases
- Capsid Proteins
- Escherichia coli
- Host-Pathogen Interactions
- Protein Biosynthesis
- RNA, Messenger
- T-Phages